Asset
Linavonkibart
Scholar Rock Holding Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04291079 | phase1 | completed | 2020-04-23 | 2025-04-14 | Scholar Rock, Inc. | SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) |
FDA applications (0)
This company has no applications containing this asset.